公司概覽
業務類別 Biotechnology
業務概覽 Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator ofthe alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
公司地址 14 Milliston Road, Box 195, Millis, MA, USA, 02054
電話號碼 +1 339 240-6066
傳真號碼 --
公司網頁 https://www.neuphoriatx.com
員工數量 1
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Timothy M. Cunningham Chief Financial Officer -- 18/09/2026
Dr. Spyros Papapetropoulos, M.D.,PhD Interim Chief Executive Officer and Director 美元 284.63K 18/09/2026
 
董事會成員
董事會 職務 更新日期
Mr. Peter Miles Davies Independent Director 18/09/2026
Mr. Alan Fisher Chairman of the Board 18/09/2026
Dr. Jane Ryan, PhD Independent Director 18/09/2026
Mr. David Wilson Director 18/09/2026
Dr. Spyros Papapetropoulos, M.D.,PhD Interim Chief Executive Officer and Director 18/09/2026
 
所屬ETF (更新日期: 07/11/2026 02:03)
代號 名稱 佔比% ▼ 持有日期
PSILAdvisorShares Psychedelics ETF5.37%30/10/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.